Second allogeneic stem cell transplantation for XMEN disease. [PDF]
Wirk B.
europepmc +1 more source
Case Report: autologous stem cell boost enables hematopoietic recovery after severe cytopenia induced by BCMA-targeted bispecific antibody therapy in multiple myeloma. [PDF]
Akiyama H +12 more
europepmc +1 more source
Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market.
Abdelaziz A +3 more
europepmc +1 more source
Severe Late-Onset Neutropenia in a Patient With Multiple Sclerosis Treated With Ocrelizumab. [PDF]
Mansour MK +4 more
europepmc +1 more source
The Optimal Timing and Duration of Daily G-CSF for the Primary Prevention of Febrile Neutropenia in Breast Cancer Patients Undergoing Adjuvant TAC Chemotherapy. [PDF]
Kim Z +7 more
europepmc +1 more source
Temporal Trends in the Prescription of Biosimilars and the Status of Switching from Original Biologics to Biosimilars at Individual and Institutional Levels in Japan. [PDF]
Matsumoto M +11 more
europepmc +1 more source
Febrile neutropenia caused by the rare organism <i>Phytobacter</i>: first Case Report from India. [PDF]
Swamy AM +6 more
europepmc +1 more source
Bridging the preparedness gap: a systematic review of recommended stockpile items for radiological and nuclear emergencies. [PDF]
Nocci M +13 more
europepmc +1 more source
Successful Treatment of Neutropenia Associated With T-Cell Large Granular Lymphocytic Leukemia Using Fludarabine. [PDF]
Uemura Y, Togitani K, Kumon Y.
europepmc +1 more source
FLT3 inhibitor and venetoclax therapy in elderly patients with relapsed/refractory <i>FLT3-ITD</i>+ AML: A report of three cases. [PDF]
Ikeda D +8 more
europepmc +1 more source

